Literature DB >> 7769294

Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil.

W R Weiss1, A J Oloo, A Johnson, D Koech, S L Hoffman.   

Abstract

Primaquine was tested as a prophylactic drug against Plasmodium falciparum in a region in western Kenya in which malaria is holoendemic. Children 9-14 years old were randomized to receive regimens of daily primaquine, daily doxycycline, daily proguanil plus weekly chloroquine, daily vitamin plus weekly mefloquine, or daily vitamin alone. Primaquine, doxycycline, and mefloquine were equally effective in preventing both symptomatic and asymptomatic malarial infections. Chloroquine plus proguanil was the least effective regimen. There was no toxicity from daily primaquine during the 11 weeks of the study. Findings show that primaquine can be successfully used as a causal prophylactic regimen against falciparum malaria in western Kenya; chloroquine plus proguanil was not as efficacious as the three other preventive regimens; most Kenyan children receiving standard doses of mefloquine and doxycycline had lower than expected serum trough drug levels; and some volunteers with adequate mefloquine or doxycycline levels at trough developed asymptomatic parasitemias and clinical malaria.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769294     DOI: 10.1093/infdis/171.6.1569

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  The evolution of tafenoquine--antimalarial for a new millennium?

Authors:  W Peters
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

2.  From Livingstone to ecotourism. What's new in travel medicine?

Authors:  S Houston
Journal:  Can Fam Physician       Date:  2000-01       Impact factor: 3.275

3.  In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron.

Authors:  B Pradines; C Rogier; T Fusai; J Mosnier; W Daries; E Barret; D Parzy
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Prevention and treatment of vivax malaria.

Authors:  J Kevin Baird; Eli Schwartz; Stephen L Hoffman
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 5.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

6.  Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis.

Authors:  D J Fryauff; A L Richards; J K Baird; T L Richie; E Mouzin; E Tjitra; M A Sutamihardja; S Ratiwayanto; H Hadiputranto; R P Larasati; N Pudjoprawoto; B Subianto; S L Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 7.  Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.

Authors:  Brice Campo; Omar Vandal; David L Wesche; Jeremy N Burrows
Journal:  Pathog Glob Health       Date:  2015-04-18       Impact factor: 2.894

8.  STATEMENT ON PEDIATRIC TRAVELLERS: Committee to Advise on Tropical Medicine and Travel.

Authors:  S Kuhn; C Hui
Journal:  Can Commun Dis Rep       Date:  2010-06-10

9.  Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline.

Authors:  Sébastien Briolant; Meili Baragatti; Philippe Parola; Fabrice Simon; Adama Tall; Cheikh Sokhna; Philippe Hovette; Modeste Mabika Mamfoumbi; Jean-Louis Koeck; Jean Delmont; André Spiegel; Jacky Castello; Jean Pierre Gardair; Jean Francois Trape; Maryvonne Kombila; Philippe Minodier; Thierry Fusai; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

Review 10.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.